Quick Answer
Nurix Therapeutics, Inc. reported Operating Income of -$285.67 million for fiscal year 2025.
Nurix Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$285.67M | -34.1% |
| 2024 | -$213.03M | -37.4% |
| 2023 | -$155.06M | +15.7% |
| 2022 | -$183.87M | -56.0% |
| 2021 | -$117.89M | -81.4% |
| 2020 | -$64.98M | -192.2% |
| 2019 | -$22.24M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| August 31, 2025 | -$91.39M | -67.3% | -89.1% |
| May 31, 2025 | -$48.32M | +0.4% | +23.1% |
| February 28, 2025 | -$62.86M | -39.0% | -15.1% |
| August 31, 2024 | -$54.61M | -36.5% | -12.5% |
| May 31, 2024 | -$48.54M | -81.4% | -7.3% |
| February 29, 2024 | -$45.22M | -5.3% | -13.0% |
| August 31, 2023 | -$40.01M | +14.4% | -49.5% |
| May 31, 2023 | -$26.77M | +41.5% | +37.7% |
- Nurix Therapeutics, Inc. showed a decrease of -34.1% in Operating Income compared to the prior fiscal year.
- Over the 2019–2025 period, Nurix Therapeutics, Inc.’s operating income has declined by 1184.7% (from -$22.24 million to -$285.67 million).
- The most recent figure is from Nurix Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on January 28, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: